Results 241 to 250 of about 8,164,322 (359)

Multiple sclerosis patient-reported outcomes of pharmacotherapy clinic drug utilization programs; a controlled pre-post study of self-injectable disease-modifying therapies. [PDF]

BMC Res Notes
Mohammadnezhad G, Khajeamiri Y, Khosravani S, Pourbala H, Esmaily H.   +4 more
europepmc   +1 more source

Glycemic control and cost-effectiveness attained by the drug utilization of oral antidiabetic agents in a tertiary care hospital in South India

, 2016
Nirmal George, Ajith PV, Sujatha Vijayalekshmi   +2 more
openalex   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy. [PDF]

Medicina (Kaunas)
Perrone V, Usala M, Veronesi C, Cappuccilli M, Degli Esposti L.   +4 more
europepmc   +1 more source

Validation and Utilization of Poultry Liver Microsomes for the In Vitro Evaluation of Drug-Drug Interactions

, 2021
Philip A. Russell
openalex   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Impact of supply chain disruptions and drug shortages on drug utilization: A scoping review protocol. [PDF]

PLoS One
Santhireswaran A, Ho M, Fuller K, Gaudette E, Burry L, Tadrous M.   +5 more
europepmc   +1 more source

Drug Delivery by Utilizing Oligopeptide Transporter.

, 1999
Ikumi Tamai
openalex   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Scoping review of anticancer drug utilization in lung cancer patients at the end of life. [PDF]

Clin Transl Oncol
Szigethy E, Merzah M, Sola I, Urrútia G, Bonfill X.   +4 more
europepmc   +1 more source